Table 1.
Patient characteristics at WCD prescription and 3-month follow-up; SD = standard deviation; LVEF = left ventricular ejection fraction; WCD = wearable cardioverter–defibrillator.
| Patient Characteristics | Baseline (n = 276) |
3-Month Follow-Up (n = 271) |
|---|---|---|
| NYHA functional class (mean ± SD) | 2.6 ± 0.8 | 2.0 ± 0.6 |
| LVEF (%; mean ± SD) | 25.3 ± 8.5 | 34.1 ± 10.3 |
| Beta-blocker (n, %) | 260 (94.2) | 255 (94.1) |
| % target dose (mean ± SD) | 51.6 ± 28.0 | 62.5 ± 29.7 |
| Renin–angiotensin system inhibitor (n, %) | 264 (95.7) | 265 (97.8) |
| % target dose (mean ± SD) | 47.9 ± 28.4 | 61.8 ± 31.7 |
| Mineralocorticoid receptor antagonist (n, %) | 233 (84.4) | 235 (86.7) |
| % target dose (mean ± SD) | 46.1 ± 23.4 | 54.2 ± 28.9 |
| Diuretics (n, %) | 217 (78.6) | 213 (78.6) |
| Digitalis (n, %) | 25 (9.1) | 20 (7.4) |
| Ivabradine (n, %) | 57 (20.7) | 48 (17.7) |